elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
PCA3
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
PCA3
RIS
0.000
(Research Intensity Score)
Papers
32
Top papers
Gold–Graphene Quantum Dot Hybrid Nanoparticle for Smart Diagnostics of Prostate Cancer
2024 · 15 citations
Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen
2022 · 33 citations
Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review)
2025 · 5 citations
New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
2018 · 84 citations
Aberrantly glycosylated PSMA in urine as a potential marker for prostate cancer
2025 · 3 citations
LncRNA PCA3 promotes antimony-induced lipid metabolic disorder in prostate cancer by targeting MIR-132-3 P/SREBP1 signaling
2021 · 25 citations
Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment
2025 · 2 citations
Tumor Differentiation and the Role of Nuclear Medicine Scintigraphy and Therapy
2025 · 2 citations
Time-Resolved Förster Resonance Energy Transfer Nanoassay Based on CdTe Quantum Dots for Sensitive Detection of Prostate Cancer Antigen 3
2025 · 3 citations
Newest papers
First-in-human tandem Terbium-161 and Actinium-225 PSMA radioligand therapy in metastatic castration-resistant prostate cancer
2026 · 1 citations
[177Lu]Lu-PSMA-617 in metastatic androgen pathway modulator-sensitive prostate cancer
2026
Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report
2026
Supplementary Figures S1 - S10 from Clonal Hematopoiesis after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
2026
Early changes in blood-based immune gene expression as a predictor of outcomes of 177 LuPSMA radioligand therapy in metastatic castration-resistant prostate cancer.
2026
P0040 Prognostic impact of TP53 alterations in metastatic castration-resistant prostate cancer treated with [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy
2026
Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review)
2025 · 5 citations
Aberrantly glycosylated PSMA in urine as a potential marker for prostate cancer
2025 · 3 citations
Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment
2025 · 2 citations
Browse all papers →
PCA3's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
PCA3's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link